tuberoside: a steroidal saponin from the seeds of Allium tuberosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Allium | genus | A genus of the plant family Amaryllidaceae. Many produce pungent, often bacteriostatic and physiologically active compounds and are used as VEGETABLES; CONDIMENTS; and medicament, the latter in traditional medicine.[MeSH] | Amaryllidaceae | A family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 70685270 |
| CHEMBL ID | 2012310 |
| CHEBI ID | 172764 |
| MeSH ID | M0401748 |
| Synonym |
|---|
| CHEBI:172764 |
| tuberoside |
| (2r,3r,4s,5s,6r)-2-[[(3s,5r,6r,9s,10r,13r,14r,17r)-17-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-5,6-dihydroxy-10,13-dimethyl-1,2,3,4,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
| CHEMBL2012310 |
| 140447-21-8 |
| DTXSID101154063 |
| (3beta,5alpha,6beta,22e)-5,6-dihydroxyergosta-7,22-dien-3-yl beta-d-glucopyranoside |
| Class | Description |
|---|---|
| steroid saponin | Any saponin derived from a hydroxysteroid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID652956 | Inhibition of NGF-mediated neurite outgrowth in rat PC12 cells after 24 hrs by light microscopy | 2012 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7 | Scabronine M, a novel inhibitor of NGF-induced neurite outgrowth from PC12 cells from the fungus Sarcodon scabrosus. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||